Contrasting Artelo Biosciences (NASDAQ:ARTL) & Tenax Therapeutics (NASDAQ:TENX)

Artelo Biosciences (NASDAQ:ARTL) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Insider and Institutional Ownership

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Artelo Biosciences and Tenax Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88 million	($32.74)	-0.03
Tenax Therapeutics	N/A	N/A	-$52.60 million	($1.40)	-10.39

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Artelo Biosciences and Tenax Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1	2	0	0	1.67
Tenax Therapeutics	1	0	5	1	2.86

Artelo Biosciences currently has a consensus price target of $54.00, indicating a potential upside of 4,721.43%. Tenax Therapeutics has a consensus price target of $38.00, indicating a potential upside of 161.17%. Given Artelo Biosciences’ higher probable upside, equities analysts clearly believe Artelo Biosciences is more favorable than Tenax Therapeutics.

Profitability

This table compares Artelo Biosciences and Tenax Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Risk & Volatility

Artelo Biosciences has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Tenax Therapeutics beats Artelo Biosciences on 9 of the 12 factors compared between the two stocks.

About Artelo Biosciences

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

About Tenax Therapeutics

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.